Dyne Therapeutics (DYN) AI Stock Analysis

• Market Cap: $1.31B
• Dividend Yield: N/A
• Average Volume (3M): 3.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.19
• Revenue Growth: N/A
• EPS Growth: 14.93%
• Country: US
• Employees: 192
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.05
• Shares Outstanding: 141,545,360
• 10 Day Avg. Volume: 2,636,013
• 30 Day Avg. Volume: 3,207,528
• PEG Ratio: 0.35
• Price to Book (P/B): 1.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.63
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: 95.44
• Enterprise Value/Gross Profit: -1.81K
• Enterprise Value/Ebitda: -0.55
• 1Y Price Target: $37.54
• Price Target Upside: 306.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 43 Neutral
• Price Target: ―

Dyne Therapeutics' stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.

Positive Factors

Competitive Positioning

Having vHOT as a primary endpoint for an accelerated approval is encouraging for Dyne’s clinical and commercial strategy.

Regulatory Progress

Dyne announced FDA Breakthrough Therapy Designation and updated plan for accelerated approval in myotonic dystrophy type 1.

Treatment Efficacy

DYNE-101 delivers consistent and sustained treatment benefits, showing improvement in myotonia, muscle strength, mobility, and patient-reported outcomes, with consistent safety.

Negative Factors

Endpoint Change Skepticism

The change from splicing to vHOT represents a significant shift that may cause confusion and skepticism among investors.

Investor Concerns

The pivot to vHOT as the primary endpoint, differing from the original CASI-22 plan, could trigger investor concerns due to previous high conviction in CASI-22.

Dyne Therapeutics Business Overview & Revenue Model

Company Description

Dyne Therapeutics (DYN) is a biotechnology company focused on developing targeted therapies for patients with genetically driven diseases. The company specializes in advancing innovative treatments for rare muscle disorders, leveraging its proprietary FORCE platform to deliver nucleic acid therapeutics precisely to muscle tissue. Dyne's pipeline includes programs aimed at treating conditions such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.

How the Company Makes Money

Dyne Therapeutics generates revenue primarily through strategic collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments for achieving specific clinical or regulatory goals, and royalties on sales of any successfully commercialized products. Additionally, Dyne may receive funding through research grants and government contracts aimed at advancing its therapeutic programs. As the company progresses towards commercialization, potential revenue streams could also include direct sales of approved therapies or sublicensing opportunities with other entities.

Dyne Therapeutics Financial Statement Overview

Summary

Dyne Therapeutics exhibits characteristics typical of an early-stage biotech firm: significant cash reserves and low leverage support its R&D focus, despite zero revenue and increasing net losses. The strong balance sheet mitigates the risks associated with negative cash flows, contingent on future breakthroughs and commercialization.

Income Statement

Dyne Therapeutics has consistently reported zero revenue over the years, reflecting its early-stage position in the biotechnology sector focused on R&D. The company incurs substantial net losses, which have been increasing over time, indicating high operational expenses without offsetting revenue streams. This results in negative profit margins across all metrics, which is typical for a biotech firm in the pre-commercial phase.

Balance Sheet

The balance sheet is relatively strong with a significant amount of cash and short-term investments, which is crucial for sustaining R&D activities. The company maintains low debt levels relative to its equity, reflected in a healthy debt-to-equity ratio. A robust equity ratio indicates a strong capital structure, providing financial stability and reducing immediate liquidity risks.

Cash Flow

Cash flows are deeply negative, driven by heavy R&D investments, a common scenario for pre-revenue biotech companies. However, the substantial cash on hand and positive financing cash flow from equity funding highlight the company's ability to raise capital, enabling it to continue its development projects despite negative free cash flow growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-2.46M	-3.35M	-1.09M	-700.00K
EBITDA	-315.18M	-233.48M	-164.75M	-148.20M	-58.34M
Net Income	-317.42M	-235.94M	-165.24M	-149.28M	-58.74M
Balance Sheet
Total Assets	691.23M	165.08M	306.32M	425.66M	353.33M
Cash, Cash Equivalents and Short-Term Investments	642.27M	123.10M	256.01M	376.57M	345.31M
Total Debt	23.99M	27.41M	30.48M	32.64M	0.00
Total Liabilities	61.40M	73.79M	53.96M	57.47M	10.97M
Stockholders Equity	629.84M	91.29M	252.36M	368.20M	342.37M
Cash Flow
Free Cash Flow	-294.75M	-188.89M	-156.71M	-123.18M	-47.67M
Operating Cash Flow	-292.37M	-188.16M	-153.65M	-119.56M	-46.51M
Investing Cash Flow	-204.08M	83.31M	87.20M	-137.89M	-45.66M
Financing Cash Flow	809.89M	54.32M	37.39M	157.82M	380.69M

Dyne Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Neutral. The current price of 9.24 is above the 20-day moving average (MA) of 9.02, below the 50-day MA of 11.05, and below the 200-day MA of 17.41, indicating a neutral trend. The MACD of -0.50 indicates Negative momentum. The RSI at 44.54 is Neutral, neither overbought nor oversold. The STOCH value of 65.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DYN.

Dyne Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥355.44B	11.10	-2.99%	2.49%	11.76%	-10.16%
VRDN	61 Neutral	$1.43B	―	-49.41%	―	4.86%	10.13%
WVE	58 Neutral	$1.33B	―	-105.50%	―	-7.06%	-57.17%
IOVA	57 Neutral	$1.33B	―	-51.85%	―	11070.12%	32.07%
SNDX	48 Neutral	$859.61M	―	-93.70%	―	―	-25.83%
DYN	43 Neutral	$1.31B	―	-64.01%	―	―	14.93%
ELVN	36 Underperform	$1.29B	―	-31.30%	―	―	12.85%

Dyne Therapeutics Corporate Events

Dyne Therapeutics Appoints Erick Lucera as CFO

On March 20, 2025, Dyne Therapeutics announced the appointment of Erick Lucera as Chief Financial Officer and Treasurer, effective March 31, 2025. This strategic move follows Lucera’s extensive experience in financial leadership roles within the biotechnology sector, notably at Editas Medicine and AVEO Pharmaceuticals. His appointment coincides with the departure of Richard Scalzo, who will transition to a consulting role. These changes are expected to enhance Dyne Therapeutics’ financial strategy and operational efficiency, potentially impacting its market positioning positively.